Eisai links up with UK charity on dementia research

8 May 2019

Japanese pharma major Eisai (TYO: 4523) knows from its own setbacks how challenging R&D in dementia is, but the company is not giving up and is now linking up with a UK charity to accelerate research.

The partnership with the UK Dementia Research Institute (UK DRI) is aimed at delivering innovative research that translates into improvements in diagnosis, treatment and prevention of all types of dementia.

As the aging of the global population gathers pace, the number of dementia patients worldwide is expected to reach 82 million in 2030 and 152 million in 2050.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK